<DOC>
	<DOCNO>NCT01146990</DOCNO>
	<brief_summary>In continue effort understand benefit risk utero exposure 17P study design evaluate difference developmental outcomes child , age 23 25 month , born mother participate 17P Efficacy Trial sponsor Hologic ( Protocol number 17P-ES-003 ) .</brief_summary>
	<brief_title>A Prospective , Noninterventional Follow-Up Study Children Aged 23 25 Months , Born Mothers Who Received Hydroxyprogesterone Caproate Injection , 250 mg/mL , Vehicle Prevention Preterm Birth</brief_title>
	<detailed_description>This prospective , noninterventional follow-up study design provide developmental assessment child bear mother participate 17P Efficacy Trial . When subject reach age 23 month adjustment gestational age , screen developmental delay use 24 month ASQ version 3 . Subjects score positive ( fall specify cut-off ) developmental delay 1 domain refer 24 month Bayley Scales Infant Toddler Development ( 3rd edition , Bayley-III ) neurological examination .</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>17-alpha-hydroxy-progesterone caproate</mesh_term>
	<mesh_term>11-hydroxyprogesterone</mesh_term>
	<criteria>1 . Maternal enrollment result live birth 17P Efficacy Trial : A Multicenter , Randomized , Doubleblind Study Hydroxyprogesterone Caproate Injection , 250 mg/mL , Versus Vehicle Prevention Preterm Birth Women With Previous Singleton Spontaneous Preterm Delivery . 2 . During involvement protocol , mother must receive least one dose study drug ( Safety population ) . 3 . Children 22 25 month age adjust gestational age . 1 . There parent/legal guardian available sign inform consent . 2 . Born woman unblinded study group assignment .</criteria>
	<gender>All</gender>
	<minimum_age>22 Months</minimum_age>
	<maximum_age>25 Months</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>17P Efficacy Trial Follow</keyword>
</DOC>